Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Healthy Volunteer
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Volunteers, Schizophrenia
Interventions: TAK-041, TAK-041 Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: Decitabine, Tetrahydrouridine; Drug
Lead sponsor: EpiDestiny, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Topiramate; Drug
Lead sponsor: Torrent Pharmaceuticals Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Safety in Asthma Patients
Interventions: ASY202, Placebo; Combination Product
Lead sponsor: Aspeya, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Glendale, Arizona • Anaheim, California • San Antonio, Texas

Conditions: Chronic Idiopathic Constipation
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Anniston, Alabama • Anaheim, California • DeLand, Florida + 8 more

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Autism Spectrum Disorders
Interventions: Double blind phase Placebo Nasal Spray, double Blind Oxytocin Nasal Spray, Open Label intranasal oxytocin; Drug
Lead sponsor: Linmarie Sikich; Other
Eligibility: 3 Years to 17 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: Boston, Massachusetts • New York, New York • White Plains, New York + 3 more

Conditions: Bioequivalence
Interventions: 12.5 mg Androxal Formulation A, 12.5 mg Androxal Formulation B, 25 mg Androxal Formulation A, 25 mg Androxal Formulation B; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ocular Redness
Interventions: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify® (brimonidine tartrate ophthalmic solution 0.025%); Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 6
States / cities: Colorado Springs, Colorado • Louisville, Kentucky • Andover, Massachusetts + 3 more

Conditions: Hypertension
Interventions: CTX340, Placebo; Drug
Lead sponsor: CRISPR Therapeutics AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Port Orange, Florida

Conditions: Epidermolysis Bullosa Simplex
Interventions: diacerein 1% ointment, A placebo ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 4 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 8 more

Conditions: Hidradenitis Suppurativa
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more

Conditions: Pain, Postoperative
Interventions: Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine; Drug · Other
Lead sponsor: Neumentum, Inc.; Other
Eligibility: 18 Years to 64 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more

Conditions: Thyroid Eye Disease
Interventions: Teprotumumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Miami, Florida • St Louis, Missouri • Bellaire, Texas

Conditions: Healthy
Interventions: Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF), Tapentadol Prolonged-Release Formulation 2 (PR2); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions: BMS-986165 Capsule, BMS-986165 Tablet; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
Interventions: Abiraterone acetate, Apalutamide, Enzalutamide; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 9 more

Conditions: Kidney Transplant
Interventions: Valganciclovir; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 68 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS); Biological · Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Osteoarthritis, Fibromyalgia
Interventions: NEM Formulation X, NEM Formulation Y; Dietary Supplement
Lead sponsor: ESM Technologies, LLC; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Jenks, Oklahoma

Conditions: Solid Tumors
Interventions: Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 32
States / cities: Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Orlando, Florida • Henderson, Nevada + 3 more

Conditions: Hypogonadism
Interventions: Test formulation, Reference formulation; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: DeLand, Florida • Miami, Florida

Search by objective public record fields.

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors

Comparison of Two Formulations of Androxal

"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

A Study of Two Formulations of LY3074828 in Healthy Participants

Efficacy & Safety Study of Natural Eggshell Membrane (NEM) for the Treatment of Joint & Connective Tissue Disorders

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males